Johnson & Johnson (NYSE:JNJ) is Zurcher Kantonalbank Zurich Cantonalbank’s 10th Largest Position
Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in shares of Johnson & Johnson (NYSE:JNJ) by 4.1% in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,039,519 shares of the company’s stock after purchasing an additional 40,509 shares during the period. Johnson & Johnson comprises 1.3% of Zurcher Kantonalbank Zurich Cantonalbank’s investment portfolio, making the stock its 10th biggest position. Zurcher Kantonalbank Zurich Cantonalbank’s holdings in Johnson & Johnson were worth $136,312,000 as of its most recent filing with the Securities & Exchange Commission.
Other hedge funds also recently added to or reduced their stakes in the company. Houlihan Financial Resource Group Ltd. purchased a new stake in shares of Johnson & Johnson during the fourth quarter worth about $1,376,000. Bowen Hanes & Co. Inc. increased its stake in shares of Johnson & Johnson by 11.5% during the fourth quarter. Bowen Hanes & Co. Inc. now owns 362,432 shares of the company’s stock worth $52,868,000 after purchasing an additional 37,290 shares in the last quarter. Community Financial Services Group LLC increased its stake in shares of Johnson & Johnson by 2.6% during the fourth quarter. Community Financial Services Group LLC now owns 25,571 shares of the company’s stock worth $3,730,000 after purchasing an additional 645 shares in the last quarter. Chelsea Counsel Co. increased its stake in shares of Johnson & Johnson by 3.9% during the fourth quarter. Chelsea Counsel Co. now owns 45,344 shares of the company’s stock worth $6,614,000 after purchasing an additional 1,693 shares in the last quarter. Finally, Csenge Advisory Group grew its stake in Johnson & Johnson by 18.7% during the 4th quarter. Csenge Advisory Group now owns 13,480 shares of the company’s stock valued at $1,966,000 after acquiring an additional 2,127 shares in the last quarter. 67.66% of the stock is owned by institutional investors and hedge funds.
NYSE:JNJ opened at $144.37 on Friday. The company’s 50-day moving average is $146.81 and its two-hundred day moving average is $142.30. The company has a debt-to-equity ratio of 0.41, a current ratio of 1.31 and a quick ratio of 1.05. Johnson & Johnson has a 1-year low of $109.16 and a 1-year high of $157.00. The firm has a market capitalization of $386.52 billion, a price-to-earnings ratio of 19.10, a PEG ratio of 3.19 and a beta of 0.71.
The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 9th. Stockholders of record on Tuesday, May 26th will be issued a $1.01 dividend. This is a positive change from Johnson & Johnson’s previous quarterly dividend of $0.95. This represents a $4.04 annualized dividend and a dividend yield of 2.80%. The ex-dividend date is Friday, May 22nd. Johnson & Johnson’s dividend payout ratio is currently 43.78%.
In related news, Director William D. Perez acquired 500 shares of the firm’s stock in a transaction dated Friday, March 13th. The shares were purchased at an average cost of $127.69 per share, for a total transaction of $63,845.00. Following the acquisition, the director now owns 16,030 shares in the company, valued at approximately $2,046,870.70. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Corporate insiders own 0.27% of the company’s stock.
Several analysts recently issued reports on JNJ shares. Morgan Stanley upped their price objective on shares of Johnson & Johnson from $160.00 to $170.00 and gave the company an “overweight” rating in a research note on Wednesday, April 29th. Argus reaffirmed a “buy” rating and set a $155.00 price objective (down previously from $165.00) on shares of Johnson & Johnson in a research note on Friday, March 27th. Bank of America raised shares of Johnson & Johnson from a “neutral” rating to a “buy” rating and upped their price objective for the company from $150.00 to $175.00 in a research note on Wednesday, April 22nd. Raymond James upped their price objective on shares of Johnson & Johnson from $153.00 to $157.00 and gave the company an “outperform” rating in a research note on Wednesday, April 15th. Finally, SVB Leerink dropped their price objective on shares of Johnson & Johnson from $172.00 to $160.00 and set an “outperform” rating for the company in a research note on Wednesday, April 8th. Four analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company’s stock. The stock has an average rating of “Buy” and an average price target of $163.47.
About Johnson & Johnson
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
Featured Article: What is systematic risk?
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.